Giraffe Bio Raises $6.4M to Lift Copper Recovery With Tailored Biomolecules
Giraffe Bio has raised a $6.4 million seed round led by Orion Industrial Ventures. The financing was reported on Oct. 13, 2026, with co-founder and CEO Alejandro Buffo Sempé leading the company TechCrunch.
The round included BHP Ventures, Twynam, Air Capital and Baruch Future Ventures. The syndicate pairs industrial and mining capital with early-stage backers focused on future-facing materials.
Giraffe Bio develops mineral-specific chemicals intended to help mines recover up to 5% more copper. The products are bespoke biomolecules, custom-built biological chemicals designed for selectivity, the ability to favor one target mineral, rather than bulk commodity reagents that act broadly.
Production starts with engineered microbes grown in a bioreactor. The resulting chemicals are then inserted into a mine's existing process. The pitch is yield without rebuild.
In practice, the compounds go into flotation, the standard method for concentrating sulfide ores, where chemistry controls what floats for collection and what is left behind. Giraffe Bio is positioning its products as a drop-in addition to that circuit.
That fit helps adoption. Mines rarely replace grinding, conditioning or flotation cells for a new reagent. A product that doses into installed equipment faces fewer barriers than one that needs new unit operations, new water balances or retraining across shifts.
The company says its platform can be tuned for minerals beyond copper, including gold and silver. The first focus is copper, where demand is linked to the AI data center boom and economy-wide electrification, according to TechCrunch reporting.
Looking at what this means for operators and investors, the claim to test is selectivity at scale. Lab specificity is one problem. Plant stability is another. Flotation feeds vary by ore body, grind size, pH, water chemistry and the mix of gangue minerals, the unwanted rock, in any given week. A biomolecule that performs in a controlled cell must hold its advantage through that variability, batch after batch, without trading grade, the purity of the concentrate, for recovery, the share of metal captured, or adding downstream complications.
In my view, the commercial question is as important as the biological one. Bioreactor production offers precise control over molecular structure, but mining consumes reagents by the ton and buys on cost per ton of metal recovered. Giraffe Bio will need to show consistent dosage, shelf life, logistics and unit economics that survive procurement review, not only metallurgical review. Strategic participation from mining-linked investors helps here, because access to ore samples and pilot circuits is often the gating factor for reagent startups.
The broader context here is familiar to anyone who has watched process industries absorb biotechnology. The winners tend to be incremental on the outside and sophisticated on the inside. They leave the plant alone and change the molecule. If Giraffe Bio can document a repeatable recovery uplift across different feeds while holding grade, even low-single-digit gains compound into meaningful metal over a mine life and expand what counts as economic ore.
